Credence

Sanofi Weighs Potential Acquisition of Insmed to Strengthen Respiratory Pipeline


Key Points

  • Sanofi is evaluating a potential acquisition of Insmed, with discussions uncertain and no agreement reached, according to NAI500
  • A deal could be the largest biopharma acquisition since Pfizer's $43 billion Seagen purchase; Insmed shares closed up 20.58%
  • Insmed markets Brinsupri and Arikayce, with third-quarter revenue up 268% year over year to $524.4 million

Sanofi is considering a potential acquisition of U.S.-based biopharmaceutical company Insmed, a move that could significantly expand its respiratory medicine portfolio and rank among the largest transactions in the biopharma sector in recent years, according to a report by NAI500.

People familiar with the matter told NAI500 that Sanofi is evaluating the possibility of a deal, although discussions remain uncertain and no agreement has been reached. The potential transaction would support Sanofi’s broader effort to strengthen its pipeline through business development and acquisitions, as it looks to secure additional growth drivers and offset future revenue pressures from patent expirations.

A deal could represent the largest biopharma acquisition since Pfizer completed its $43 billion purchase of Seagen in late 2023. News of Sanofi’s potential interest sent Insmed shares sharply higher, with the stock closing up 20.58% during Thursday’s U.S. trading session after gaining more than 23% intraday. Sanofi shares moved in the opposite direction, falling more than 2%.

Insmed’s respiratory portfolio appears to be a key attraction. The company markets Brinsupri for non-cystic fibrosis bronchiectasis and Arikayce for refractory Mycobacterium avium complex lung disease. Insmed recently raised the lower end of its 2026 revenue outlook for the two products. Its third-quarter revenue increased 268% year over year to $524.4 million, reflecting growing commercial momentum.

Beyond its marketed medicines, Insmed has a pipeline of investigational therapies targeting respiratory conditions, as well as programs in immunology, inflammation and neurological diseases. Analysts cited in the NAI500 report see strategic alignment between the companies, noting that Sanofi’s established global commercial infrastructure could help expand the reach of Insmed’s respiratory products.

Sanofi has faced investor expectations to replenish its pipeline with late-stage or commercially established assets. The company is seeking new sources of growth as it prepares for the eventual loss of exclusivity for Dupixent, one of its most important products. Since taking the chief executive role, Belén Garijo has emphasized acquisitions as an important component of Sanofi’s growth strategy. The company has also identified rare diseases as a priority area for investment, with management showing interest in assets that are already commercialized or approaching the market.

A potential Insmed deal would come as Sanofi works through pipeline and strategic challenges. Several clinical trial results have fallen short of expectations, and the company is expected to outline its latest strategic priorities by year-end. The outcome of any discussions with Insmed, including the possibility of competing interest from other pharmaceutical companies, remains unclear.

Learn more about Sanofi at www.sanofi.com.